Renal Care
Key Launches:
HDX Enabled By Theranova
~50% of End Stage Renal Disease
(ESRD) patients die due to
cardiovascular disease
Effectively clears large uremic
toxins with no change in existing
infrastructure and workflow¹
May attenuate inflammation,
atherosclerosis and calcification
Baxter
Classification of uremic solutes by molecular weight
Urea (60)
Phosphate (96)
Creatinine (113)
PTH (9500)
Beta 2 microglobulin (11800)
Cystatin C (13300)
Myoglobin (17000)
Kappa free light chains (22500)
Complement factor D (24000)
Interleukin-6 (24500)
Alpha 1 microglobulin (33000)
YKL-40 (40000)
Lambda free light chains (45000)
Albumin (67000)
Portfolio
Innovation
T
20
Small
molecules
<500 Da
Conventional
Middle molecules
500-15000 Da
Large Middle
molecules
> 15000 Da
Essential
proteins
Innovation That Improves Patient Outcomes
Market
Development Adjacencies +
=+
Evolution of dialysis therapies
Kidney
Low
Flux
High Flux
HDF
1See slide 17 for reference.
HDX
| 8View entire presentation